Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by Wall Street Zen

Key Points

• Supernus Pharmaceuticals has been downgraded by Wall Street Zen from a "buy" rating to a "hold" rating, indicating a shift in analyst sentiment regarding the stock's potential.
• Despite the downgrade, analysts have mixed opinions, with ratings ranging from a "strong buy" to a "hold," and an average target price of $51.50.
• Insider trading was noted, as significant stock sales occurred, with insiders selling a total of $13.36 million worth of shares in the last quarter.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Friday.

Other research analysts have also issued reports about the stock. Weiss Ratings restated a "hold (c)" rating on shares of Supernus Pharmaceuticals in a report on Saturday, September 27th. Piper Sandler upped their price objective on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a research note on Friday, August 29th. Cantor Fitzgerald upped their price objective on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an "overweight" rating in a research note on Tuesday. Finally, Zacks Research raised Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Supernus Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $51.50.

Supernus Pharmaceuticals Trading Up 0.8%

Shares of NASDAQ:SUPN traded up $0.39 on Friday, hitting $48.35. The company had a trading volume of 939,438 shares, compared to its average volume of 676,476. Supernus Pharmaceuticals has a 52-week low of $29.16 and a 52-week high of $49.66. The business has a 50 day moving average of $43.52 and a 200 day moving average of $36.11. The company has a market cap of $2.71 billion, a PE ratio of 42.04 and a beta of 0.78.

Insider Buying and Selling

In related news, Director Bethany Sensenig sold 5,369 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $42.25, for a total value of $226,840.25. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Frederick M. Hudson sold 7,457 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $42.26, for a total transaction of $315,132.82. Following the completion of the transaction, the director owned 46,307 shares in the company, valued at $1,956,933.82. The trade was a 13.87% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 302,841 shares of company stock worth $13,361,449. Corporate insiders own 8.80% of the company's stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in SUPN. Rubric Capital Management LP purchased a new position in Supernus Pharmaceuticals in the second quarter valued at about $21,908,000. Armistice Capital LLC raised its position in Supernus Pharmaceuticals by 7.4% in the first quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock valued at $170,169,000 after purchasing an additional 360,000 shares during the period. Sofinnova Investments Inc. raised its holdings in shares of Supernus Pharmaceuticals by 53.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company's stock valued at $25,192,000 after buying an additional 278,575 shares during the period. GW&K Investment Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 14.6% during the 1st quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock valued at $45,275,000 after buying an additional 176,091 shares during the period. Finally, Nuveen LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 1st quarter valued at about $4,393,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.